390 related articles for article (PubMed ID: 15505274)
1. Adjuvant chemotherapy for elderly women with hormone receptor-positive breast cancer: an old(er) problem.
Schott A; Hayes DF
J Clin Oncol; 2004 Dec; 22(23):4660-2. PubMed ID: 15505274
[No Abstract] [Full Text] [Related]
2. Breast cancer: metastatic.
Johnston S; Stebbing J
Clin Evid; 2002 Jun; (7):1579-602. PubMed ID: 12230774
[No Abstract] [Full Text] [Related]
3. The use of aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer.
Benson JR
J Clin Oncol; 2005 Sep; 23(27):6807-9. PubMed ID: 16170197
[No Abstract] [Full Text] [Related]
4. Adjuvant treatment of breast cancer.
Akerley WL
R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
[No Abstract] [Full Text] [Related]
5. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
6. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
Pritchard KI
Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
[No Abstract] [Full Text] [Related]
7. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
8. Endocrine therapy of breast cancer.
Goldhirsch A; Colleoni M; Gelber RD
Ann Oncol; 2002; 13 Suppl 4():61-8. PubMed ID: 12401668
[No Abstract] [Full Text] [Related]
9. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
10. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
De Maeyer L; Van Limbergen E; De Nys K; Moerman P; Pochet N; Hendrickx W; Wildiers H; Paridaens R; Smeets A; Christiaens MR; Vergote I; Leunen K; Amant F; Neven P
J Clin Oncol; 2008 Jan; 26(2):335-6; author reply 336-8. PubMed ID: 18182677
[No Abstract] [Full Text] [Related]
11. [Therapy studies of the Austrian Breast Cancer Group (ABC)].
Jakesz R; Hausmaninger H; Samonigg H; Kubista E; Haider K; Mlineritsch B; Schmid M; Tausch C; Reiner G; Renner K; Stierer M; Jatzko G; Hofbauer F; Fridrik M; Schennach W; Sevelda P; Dadak C; Haid A; Scholz R; Lenzhofer P; Steindorfer P; Berger A; Mischinger HJ
Zentralbl Chir; 1998; 123 Suppl 5():28-32. PubMed ID: 10063568
[TBL] [Abstract][Full Text] [Related]
12. [Early-stage breast cancer - strategies for adjuvant systemic therapy].
Görner M; Just M; Gerull S
Handchir Mikrochir Plast Chir; 2008 Aug; 40(4):230-8. PubMed ID: 18716990
[TBL] [Abstract][Full Text] [Related]
13. Disease related indicators for a proper choice of adjuvant treatments.
Hayes DF
Breast; 2011 Oct; 20 Suppl 3():S162-4. PubMed ID: 22015287
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy in luminal breast cancers.
Lim E; Winer EP
Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
[TBL] [Abstract][Full Text] [Related]
15. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Cataliotti L; Buzdar AU; Noguchi S; Bines J; Takatsuka Y; Petrakova K; Dube P; de Oliveira CT
Cancer; 2006 May; 106(10):2095-103. PubMed ID: 16598749
[TBL] [Abstract][Full Text] [Related]
16. [Breast cancer: adjuvant hormone and chemotherapy].
Possinger K
Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990; ():83-8. PubMed ID: 1983665
[TBL] [Abstract][Full Text] [Related]
17. Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?
Papaldo P; Di Cosimo S; Ferretti G; Carlini P; Fabi A; Cecere F; Cognetti F
Breast; 2006 Apr; 15(2):269-72. PubMed ID: 16131469
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer: a short review.
Elias AD
Am J Clin Oncol; 2010 Dec; 33(6):637-45. PubMed ID: 20023571
[TBL] [Abstract][Full Text] [Related]
19. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
Mehta RS
J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
[No Abstract] [Full Text] [Related]
20. Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
Alliot C
J Clin Oncol; 2005 Jun; 23(18):4237-8; author reply 4238-9. PubMed ID: 15961776
[No Abstract] [Full Text] [Related]
[Next] [New Search]
